Physician profile
Tarun Wasil
NPI 1710949862
$147,307.58
in general payments reported to CMS, 2019-2025
28 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,138 · 2020: $1,990 · 2021: $11K · 2022: $7,233 · 2023: $23K · 2024: $51K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Consulting Fee: $27K · Travel and Lodging: $2,905 · Food and Beverage: $2,564 · Debt Forgiveness: $1,156 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $272 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,626.25 |
| Consulting Fee | $27,412.50 |
| Travel and Lodging | $2,904.58 |
| Food and Beverage | $2,564.37 |
| Debt Forgiveness | $1,156.33 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $272.25 |
| Education | $137.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43,565.02 | 2021-2025 | Ojjaara |
| Lilly USA, LLC | $30,969.01 | 2023-2025 | Jaypirca |
| Astrazeneca Pharmaceuticals LP | $27,673.63 | 2019-2025 | Calquence, Imfinzi |
| Pfizer INC. | $7,339.18 | 2020-2025 | |
| Beigene USA, INC. | $5,665.00 | 2023-2024 | Brukinsa |
| Abbvie INC. | $4,785.15 | 2022-2025 | Venclexta |
| Celgene Corporation | $4,427.71 | 2019-2022 | |
| Janssen Biotech, INC. | $3,995.54 | 2023-2025 | Tecvayli, Carvykti, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $3,823.80 | 2024-2025 | |
| Genzyme Corporation | $3,224.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $2,887.47 | 2020-2021 | |
| Adc Therapeutics America, INC. | $2,513.74 | 2023 | |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $1,300.00 | 2024 | Tazverik |
| B. Braun Medical INC. | $1,156.33 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $919.99 | 2019-2025 | |
| Boston Scientific Corporation | $364.52 | 2020-2021 | |
| Abbott Laboratories | $317.54 | 2021-2024 | Freestyle Libre 3 |
| Taiho Oncology, INC. | $169.78 | 2024 | |
| Merck Sharp & Dohme LLC | $143.37 | 2023-2024 | Keytruda |
| Medtronic, INC. | $125.00 | 2022 | |
| Daiichi Sankyo INC. | $124.99 | 2019 | |
| Exelixis INC. | $99.99 | 2023 | |
| Gilead Sciences, INC. | $95.55 | 2019-2021 | |
| Cti Biopharma Corp. | $45.08 | 2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $27.81 | 2021 | |
| Foundation Medicine, INC. | $25.69 | 2021 | |
| Sirtex Medical INC | $6.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Wasil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.